Advertisement

Brain Tumor Pathology

, Volume 28, Issue 2, pp 115–123 | Cite as

Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing

  • Shingo TakanoEmail author
  • Wei Tian
  • Masahide Matsuda
  • Tetsuya Yamamoto
  • Eiichi Ishikawa
  • Mika Kato Kaneko
  • Kentaro Yamazaki
  • Yukinari Kato
  • Akira Matsumura
Original Article

Abstract

Isocitrate dehydrogenase 1 (IDH1) mutations have recently been identified as early and frequent genetic alterations in astrocytomas, oligodendrogliomas, and oligoastrocytomas, as well as secondary glioblastomas, whereas primary glioblastomas very rarely contain IDH1 mutations. Furthermore, a specific monoclonal antibody, IMab-1, which recognizes IDH1-R132H—the most frequent IDH1 mutation—has been generated. IMab-1 has been reported to react with the IDH1-R132H protein, but not the wild-type IDH1 or the other IDH1 mutant proteins in Western-blot analysis. However, the importance of immunohistochemistry using IMab-1 has not yet been elucidated. In this study, we compared the findings from IMab-1 immunohistochemistry and direct DNA sequencing using 49 glioma samples. IMab-1 detected 12 out of 49 cases; however, only nine cases were found to be IDH1-R132H by direct DNA sequencing because of a small population of IDH1-R132H mutation-possessing tumor cells, indicating that IMab-1 immunohistochemistry is useful for detecting IDH1-R132H. We conducted immunohistochemical detection in 52 cases of grade III astrocytomas. The median time to progression (TTP) was significantly longer in the cases with the IDH1 mutation (86.7 months) compared to the cases without the IDH1 mutation (wild type, 10.4 months) (p < 0.01). In conclusion, the anti-IDH1-R132H-specific monoclonal antibody IMab-1 is very useful for detecting IDH1-R132H in immunohistochemistry, and predicting the time to progression in grade III anaplastic astrocytomas. Therefore, IMab-1 is likely to be useful for the diagnosis of mutation-bearing gliomas and for determining the treatment strategy of grade III gliomas.

Keywords

IDH1 Mutation Immunohistochemistry Monoclonal antibody Glioma 

Notes

Acknowledgments

We gratefully acknowledge Yoshiko Tsukada and Makiko Miyakawa for their excellent technical assistance, and Chifumi Kitanaka for his great suggestion. IMab-1 antibody was kindly donated by Dr. Darell D. Bigner, Duke University Medical Center. This study was supported by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science (S. T.), and by grants provided by the Tsukuba Advanced Research Alliance, the Japan Brain Foundation, the Japanese Foundation for Research and Promotion of Endoscopy, the Japanese Foundation for Multidisciplinary Treatment of Cancer (S.T.), the Global COE Program for Medical Sciences, the Japan Society for the Promotion of Science (Y. K. and M. K. K), and the Experimental and Research Center, North China Coal Medical University (W. T.).

Supplementary material

10014_2011_23_MOESM1_ESM.doc (95 kb)
Supplementary material 1 (DOC 95 kb)

References

  1. 1.
    Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998PubMedCrossRefGoogle Scholar
  2. 2.
    Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153PubMedCrossRefGoogle Scholar
  3. 3.
    Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedCrossRefGoogle Scholar
  4. 4.
    Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154PubMedCrossRefGoogle Scholar
  5. 5.
    Kato Y, Jin G, Kuan CT, McLendon RE et al (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547–551PubMedCrossRefGoogle Scholar
  6. 6.
    Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathway in the evolution of gliomas. Cancer Sci 100:2235–2241PubMedCrossRefGoogle Scholar
  7. 7.
    Capper D, Weibert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254PubMedCrossRefGoogle Scholar
  8. 8.
    Cao VT, Jung TY, Jung S et al (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866–875PubMedCrossRefGoogle Scholar
  9. 9.
    Christmann M, Nagel G, Horn S et al (2010) MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer 127:2106–2118PubMedCrossRefGoogle Scholar
  10. 10.
    Sonoda Y, Yokosawa M, Saito R et al (2010) O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15:352–358PubMedCrossRefGoogle Scholar
  11. 11.
    van den Bent MJ, Dubbink HJ, Marie Y et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597–1604Google Scholar
  12. 12.
    Boisselier B, Marie Y, Labussiere M et al (2010) COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Hum Mutat 31:1360–1365. doi: 10.1002/humu.21365 Google Scholar
  13. 13.
    Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744PubMedCrossRefGoogle Scholar
  14. 14.
    Mashiko R, Takano S, Ishikawa E et al (2010) Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image. J Neuro Oncol (Epub ahead of print)Google Scholar
  15. 15.
    Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261–265PubMedCrossRefGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2011

Authors and Affiliations

  • Shingo Takano
    • 1
    Email author
  • Wei Tian
    • 2
  • Masahide Matsuda
    • 1
  • Tetsuya Yamamoto
    • 1
  • Eiichi Ishikawa
    • 1
  • Mika Kato Kaneko
    • 2
  • Kentaro Yamazaki
    • 3
  • Yukinari Kato
    • 2
  • Akira Matsumura
    • 1
  1. 1.Department of Neurosurgery, Institute of Clinical MedicineUniversity of TsukubaTsukubaJapan
  2. 2.Molecular Tumor Marker Research Team, The Oncology Research CenterAdvanced Molecular Epidemiology Research InstituteYamagataJapan
  3. 3.Department of Forensic MedicineYamagata University Faculty of MedicineYamagataJapan

Personalised recommendations